We have observed
17 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after July 18, 2014).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
USE OF C1-INHIBITOR FOR THE TREATMENT OF SECONDARY EDEMA OF THE CENTRAL NERVOUS SYSTEM
FACTOR XII INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL INFLAMMATORY DISORDERS
COMBINATION THERAPY USING IMMUNOGLOBULIN AND C1-INHIBITOR
A METHOD FOR POLISHING ALBUMIN
A METHOD OF PURIFYING PROTEINS
RECONSTITUTED HDL FORMULATION
A METHOD OF PURIFYING THERAPEUTIC PROTEINS
THERAPEUTIC AGENT FOR AMNIOTIC FLUID EMBOLISM
TREATMENT AND PREVENTION OF REMOTE ISCHEMIA-REPERFUSION INJURY
PROCESS FOR PREPARING APOLIPOPROTEIN A-I (APO A-I)
COMBINATION THERAPY USING A FACTOR XII INHIBITOR AND A C1-INHIBITOR
CONTAMINANT REMOVAL METHOD
PHARMACEUTICAL FORMULATIONS OF C1 ESTERASE INHIBITOR
GLYCOPROTEIN V INHIBITORS FOR USE AS COAGULANTS
SOLUBLE GLYCOPROTEIN V FOR TREATING THROMBOTIC DISEASES
METHOD OF TREATING ATHEROSCLEROSIS